Reviva Pharmaceuticals (RVPH) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3 2024; topline data expected Q4 2025 – – European patent granted covering brilaroxazine use for treating pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) in any patients – - U.S. patent granted covering use of brilaroxazine for the treatment ...